Merck Animal Health shared earlier this week that the FDA approved its atinvicitinib tablets (NUMELVI; Merck Animal Health), a once daily, first line treatment for canine patients 6 months and older ...
The Board and Train program addresses anxiety, reactivity, and socialization gaps that affect nearly half of all ...